Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2026
Reporting Period: Second Quarter 2026 (Q2)
Business Focus: Clinical-stage biopharmaceutical company developing immunotherapies.
Key Financial Metrics
The filing references the issuance of a press release containing second-quarter financial results but does not explicitly state specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the text of this Form 8-K. Investors must refer to the attached Exhibit 99.1 for detailed financial data.
Material Changes and Clinical Updates
- Clinical Trial Update: The Company confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026.
- Investor Communication: An investor conference call and webcast are scheduled for August 12, 2026, at 8:30 a.m. Eastern Time to discuss the Phase 2a portion of the NEO100-01 clinical trial.
Guidance, Outlook, and Risks
Outlook: Management is focusing on the imminent presentation of Phase 2a data, which serves as a critical milestone for the NEO100 program.
Regulatory Note: The information contained in Items 2.02 and 7.01, including the attached press releases (Exhibits 99.1 and 99.2), is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific Q2 2026 financial results (revenue, cash position, and burn rate) not detailed in this summary.
- Verify the topline results of the Phase 2a NEO100 study presented on August 12, 2026.
- Listen to the investor conference call on August 12, 2026, for management commentary on the clinical data and future operational plans.
- Confirm the Company's status as an emerging growth company and any associated reporting flexibilities.